Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $190.47 and last traded at $194.00, with a volume of 107092 shares changing hands. The stock had previously closed at $208.35.
Genmab A/S Stock Performance
The firm has a market cap of $12.82 billion, a P/E ratio of 18.65 and a beta of 1.04. The business has a 50-day simple moving average of $210.47 and a 200 day simple moving average of $236.26.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
- Five stocks we like better than Genmab A/S
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- What Does the Future Hold for Eli Lilly?
- Canada Bond Market Holiday: How to Invest and Trade
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
